Effective approaches to overcome endocrine therapy (ET) resistance remain a major challenge in estrogen receptor (ER)–positive breast cancer management.1 Loss of ERα expression, a mechanism of ET resistance, is associated with tumor progression and poor clinical outcomes.1,2,3,4. The gene discussed is ESR1; the disease is neoplasm.